| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 11, 2025 |
| By Nick Paul Taylor Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, Novartis has struck a deal to buy Anthos for $925 million upfront to add the clot-busting prospect to its late-phase pipeline. |
|
|
|
By Gabrielle Masson A new initiative rolled out under President Donald Trump’s administration is cutting billions from grants for "indirect costs" tied to biomedical research, such as facilities, equipment and administrative expenses. |
By James Waldron Inventiva is going all-in on its metabolic-associated steatohepatitis drug lanifibranor—but half of its employees won’t be coming along for the ride. |
By James Waldron Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2. |
|
Join us for an expert discussion on how to navigate complex DSCSA requirements in this rapidly advancing field. Explore the systems, processes and technologies that are crucial to safeguard patients. 
|
|
By James Waldron Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky. |
By Nick Paul Taylor Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will give Agenus full control of assets that it will consider advancing internally or through new partnerships. |
By James Waldron Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis (ALS) candidate into the clinic in the coming months as the gene therapy company looks to rejig the asset’s payload. |
By Fraiser Kansteiner Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday. Merck KGaA confirmed the talks but said it's not certain a deal will come together. |
By Conor Hale Insilico also disclosed it’s begun chasing new therapeutic areas in obesity and muscle wasting conditions as well as in nonaddictive painkillers. |
By Andrea Park Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during Sunday night’s broadcast, according to TV advertising analyst EDO, but also ranked in the top 10 of all Super Bowl ads across categories. |
By Conor Hale According to the agency, BD has reported 30 serious injuries and four deaths linked to fractures or breaks within its Rotarex atherectomy systems. |
By Dave Muoio,Noah Tong The Trump administration is violating a temporary restraining order by continuing to improperly freeze federal funds—including those related to National Institutes of Health and other agencies, per a Monday order. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
